Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 979 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stability Clear all
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

NCT02000700
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 10:07 PM EDT
Terminated Phase 1 Interventional

Study Evaluating Vaccine in Adults With HIV

NCT00195312
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 20, 2026, 10:07 PM EDT
Completed No phase listed Observational

Reliability and Diagnostic Accuracy of an Alternate Lachman's Test Performed in a Prone Position

NCT01301014
View directory record Official record
Conditions
Anterior Cruciate Ligament Stability
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
15 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

NCT01922128
View directory record Official record
Conditions
Nonexudative Age-related Macular Degeneration
Interventions
MC-1101, Placebo
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 20, 2026, 10:07 PM EDT
Withdrawn Phase 2 Interventional

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

NCT04119830
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Microsatellite Stable, Mismatch Repair Proficient, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Pembrolizumab, Questionnaire Administration, Rintatolimod
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

NCT01275599
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders
Interventions
telaprevir, buprenorphine/naloxone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Results available

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

NCT01895452
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 9072, Low Dose, ALKS 9072, High Dose
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
17
States / cities
Little Rock, Arkansas • Garden Grove, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

NCT02706847
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
103
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Not applicable Interventional Results available

Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE)

NCT04938661
View directory record Official record
Conditions
Acute Myocardial Infarction, Acute Coronary Syndrome, Stable Angina Pectoris, Percutaneous Coronary Intervention, Heart Failure
Interventions
Center-Based Cardiac Rehab, mHealth, Home-Based Cardiac Rehab
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 20, 2026, 10:07 PM EDT
Terminated Not applicable Interventional

Should Graf IIc Hips be Treated for 12 Weeks

NCT03275805
View directory record Official record
Conditions
Developmental Dysplasia of Hip
Interventions
Duration of Pavlik Harness treatment, 12 week standard of care
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Weeks to 18 Weeks
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 20, 2026, 10:07 PM EDT
Active, not recruiting Not applicable Interventional

MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation

NCT05933083
View directory record Official record
Conditions
Myocardial Infarction, Heart Failure, Systolic, Heart Valve Diseases, Angina, Stable, Coronary Artery Disease, Heart Transplant
Interventions
In-person cardiac rehabilitation, Telehealth cardiac rehabilitation
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Not applicable Interventional

Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA

NCT05562037
View directory record Official record
Conditions
Angina, Stable, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
Stepped Care
Other
Lead sponsor
Peter Lindenauer, MD
Other
Eligibility
60 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Pittsfield, Massachusetts • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prosthetic Components and Stability in Amputee Gait

NCT00167778
View directory record Official record
Conditions
Diabetes Mellitus, Leg Injuries, Traumatic Amputation
Interventions
Transverse plane rotation adaptor pylon, Rigid pylon
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

NCT01288443
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Atorvastatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
38
States / cities
Tempe, Arizona • Los Angeles, California • Mission Viejo, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Not applicable Interventional

Comparison of Immediate vs Gradual Switch to Divalproex in Adults With Intellectual Disability

NCT00347152
View directory record Official record
Conditions
Epilepsy
Interventions
Divalproex
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2008 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Phase 2 Interventional Results available

A Study of Cariprazine in Patients With Chronic Stable Schizophrenia

NCT00839852
View directory record Official record
Conditions
Schizophrenia
Interventions
Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 61 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 20, 2026, 10:07 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Metabolic and Functional Consequences of Aging in Health and Disease

NCT05240885
View directory record Official record
Conditions
Aging
Interventions
Stable tracer infusion in a postabsorptive state
Other
Lead sponsor
Texas A&M University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Results available

NVA237 Versus Placebo 12-week Efficacy Study

NCT01709864
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
54
States / cities
Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 20, 2026, 10:07 PM EDT
Enrolling by invitation Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

NCT07102511
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
lerodalcibep 300 mg Monthly SC
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 10:07 PM EDT
Withdrawn Phase 2 Interventional

A Trial of LY3056480 in Patients With SNLH

NCT05061758
View directory record Official record
Conditions
Sensorineural Hearing Loss
Interventions
LY3056480
Drug
Lead sponsor
Audion Therapeutics BV
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 20, 2026, 10:07 PM EDT
Completed Phase 4 Interventional Results available

Labetalol and Esmolol: Vital Signs and Post Operative Pain Management

NCT01114971
View directory record Official record
Conditions
Laparoscopic Surgery
Interventions
Fentanyl, Labetalol, Esmolol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 20, 2026, 10:07 PM EDT
Completed No phase listed Observational

Restore EF Observational Study

NCT04648306
View directory record Official record
Conditions
Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
Interventions
Prophylactic Impella support for a non-emergent PCI
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 20, 2026, 10:07 PM EDT
Not listed No phase listed Observational

Florida Cardiovascular Quality Network

NCT02921464
View directory record Official record
Conditions
Stable Ischemic Heart Disease
Interventions
none - registry clinic followup only
Other
Lead sponsor
Florida Cardiovascular Quality Network
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Lake Mary, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 20, 2026, 10:07 PM EDT